Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
0.705
USD
|
-3.24%
|
|
-7.93%
|
-25.59%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
76.76
|
241.5
|
821.7
|
481.4
|
68.87
|
51.32
|
-
|
-
|
Enterprise Value (EV)
1 |
76.76
|
241.5
|
821.7
|
481.4
|
68.87
|
51.32
|
51.32
|
51.32
|
P/E ratio
|
-2.18
x
|
-5.49
x
|
-16.1
x
|
-6.97
x
|
-0.68
x
|
-0.56
x
|
-0.58
x
|
-0.56
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
9.84
x
|
25.7
x
|
15.4
x
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
9.84
x
|
25.7
x
|
15.4
x
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,142
|
46,268
|
49,146
|
68,378
|
72,693
|
72,801
|
-
|
-
|
Reference price
2 |
4.010
|
5.220
|
16.72
|
7.040
|
0.9474
|
0.7050
|
0.7050
|
0.7050
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/17/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
7
|
2
|
3.333
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-37.34
|
-42.95
|
-54.66
|
-71.16
|
-105.2
|
-101.7
|
-112.4
|
-135.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-1,503.39%
|
-5,084.2%
|
-3,371.07%
|
-
|
Earnings before Tax (EBT)
1 |
-35.09
|
-41.74
|
-54.63
|
-68.24
|
-101.9
|
-94.14
|
-106.2
|
-130.5
|
Net income
1 |
-35.09
|
-41.74
|
-54.63
|
-68.24
|
-101.9
|
-94.14
|
-106.2
|
-130.5
|
Net margin
|
-
|
-
|
-
|
-
|
-1,455.29%
|
-4,706.95%
|
-3,186.54%
|
-
|
EPS
2 |
-1.840
|
-0.9500
|
-1.040
|
-1.010
|
-1.400
|
-1.248
|
-1.223
|
-1.270
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/17/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
7
|
-
|
-
|
0.5
|
0.6667
|
0.8333
|
5
|
5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.1
|
-15.88
|
-16.32
|
-18.93
|
-20.03
|
-24.52
|
-26.78
|
-32.53
|
-28.4
|
-23.71
|
-24.92
|
-26.09
|
-27.37
|
-16.85
|
-17.25
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-464.67%
|
-
|
-
|
-4,984.43%
|
-3,913.08%
|
-3,284.29%
|
-337%
|
-345%
|
Earnings before Tax (EBT)
1 |
-14.21
|
-16.02
|
-16.19
|
-17.85
|
-18.18
|
-22.2
|
-24.31
|
-23.1
|
-32.26
|
-21.66
|
-22.96
|
-24.32
|
-25.87
|
-14.85
|
-15.25
|
Net income
1 |
-14.21
|
-16.02
|
-16.19
|
-17.85
|
-18.18
|
-22.2
|
-24.31
|
-23.1
|
-32.26
|
-21.66
|
-22.96
|
-24.32
|
-25.87
|
-14.85
|
-15.25
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-330.04%
|
-
|
-
|
-4,591.67%
|
-3,647.36%
|
-3,104.33%
|
-297%
|
-305%
|
EPS
2 |
-0.2500
|
-0.2600
|
-0.2500
|
-0.2500
|
-0.2500
|
-0.3100
|
-0.3400
|
-0.3200
|
-0.4400
|
-0.3000
|
-0.3133
|
-0.3217
|
-0.3250
|
-0.2000
|
-0.2100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/14/23
|
5/11/23
|
8/10/23
|
11/13/23
|
3/14/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.32
|
1.58
|
1.81
|
1
|
1
|
1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
25.86%
|
50%
|
30%
|
-
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/17/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
0.705
USD Average target price
11.67
USD Spread / Average Target +1,554.85% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.59% | 51.32M | | +12.30% | 118B | | +12.15% | 106B | | -8.14% | 23.4B | | -1.69% | 21.78B | | -10.60% | 18.09B | | -41.25% | 16.72B | | -15.33% | 15.97B | | +5.80% | 14.03B | | +28.03% | 11.67B |
Bio Therapeutic Drugs
|